I think you made a very important point when you observed that CTAD is a gathering of scientists. They know Dr. Hampel. They will be listening. And the contrast of the Anavex Precision Medicine approach to the Biogen BS will be obvious! Hopefully such a gathering of scientists will attract scientifically knowledgeable media coverage....and perhaps some well timed Cantor coverage of the stock! And if it is either preceded or followed by the announcement of Rett moving into the clinic, and/or dosing in the Alzheimer's and Parkinson's trials...there should be some share price movement...IF the 500 lb. gorilla is wanting to move it up!
Having the last spot of the day and presentation by Hampel, one of the top minds in Alzheimer's is going to be hard to discount in the eyes of professionals.
Retail investors (other than those who have really studied the stock) will be late to the party if they don't get in before CTAD.
News 
Market Data 
Discover 
